Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Capecitabine.

D R Budman1

  • 1Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA. budman@nshs.edu

Investigational New Drugs
|November 18, 2000
PubMed
Summary
This summary is machine-generated.

Capecitabine, a rationally derived prodrug of 5-fluorouracil, shows promise in cancer treatment by concentrating chemotherapy in tumors. Further research is needed to explore its full potential and manage toxicities like hand-foot syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

Leukemia & lymphoma·2016
Same author

The hedgehog pathway as a therapeutic target for treatment of breast cancer.

Breast cancer research and treatment·2009
Same author

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Current cancer drug targets·2008
Same author

Implications of applied research for prognosis and therapy of breast cancer.

Critical reviews in oncology/hematology·2008
Same author

Heparin-induced thrombocytopenia complicating hemodialysis.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2007
Same author

Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.

British journal of cancer·2003

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Drug development increasingly utilizes rationally designed agents targeting specific molecular pathways.
  • Capecitabine is a novel prodrug of 5-fluorouracil, engineered to exploit elevated thymidine phosphorylase activity in tumors.
  • Previous attempts with 5-DFUR demonstrated tumor-specific 5-fluorouracil delivery but were limited by gastrointestinal toxicity.

Purpose of the Study:

  • To evaluate the efficacy and safety profile of capecitabine as a rationally derived anticancer agent.
  • To determine the optimal dosing schedule for capecitabine in clinical trials.
  • To compare the therapeutic potential and toxicity of capecitabine with established fluoropyrimidines.

Main Methods:

  • Phase I clinical trials were conducted to assess various dosing schedules for capecitabine.

Related Experiment Videos

  • The divided oral daily x 14 schedule every 3 weeks emerged as the preferred method for Phase II and III studies.
  • Antitumor effects were evaluated in patients with malignancies known to be responsive to fluoropyrimidines.

    • Main Results:

    • Capecitabine demonstrated significant antitumor activity in responsive tumor types.
    • The divided oral daily x 14 schedule every 3 weeks was identified as the optimal dosing regimen.
    • Major dose-limiting toxicities included hand-foot syndrome, nausea/vomiting, and diarrhea.

    Conclusions:

    • Capecitabine represents a promising advancement in rationally designed cancer therapeutics, offering potential for reduced gastrointestinal toxicity compared to earlier agents.
    • The agent exhibits significant efficacy in fluoropyrimidine-sensitive cancers.
    • Further investigation is warranted to ascertain capecitabine's broader spectrum of activity across diverse tumor types and to refine toxicity management strategies.